Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

SK Bioscience Co. Ltd. gained approval from the Human Research Ethics Committee in Australia to start phase I/II trials of GBP-560, its mRNA-based vaccine candidate for mosquito-borne Japanese ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Ancient viral DNA embedded in the human genome has been linked to the genetic risks of certain neurodegenerative diseases, ...

Half of ALS patients experience constipation, which is associated with faster progression and lower survival rates, per a ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Amyotrophic Lateral Sclerosis [ALS] is a type of disorder ... there is still a chance for this program to have a pathway forward. How so? Well, the reason is that the company still has to do ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA ...